Sk Biopharmaceuticals Co Ltd Total Assets
Sk Biopharmaceuticals Co Ltd total assets. Based on the latest financial reports, Sk Biopharmaceuticals Co Ltd (326030) holds total assets worth ₩1.32 Trillion KRW (≈ $894.83 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 326030 market cap for the company's overall valuation and market capitalisation.
Total Assets of Sk Biopharmaceuticals Co Ltd (2016–2025)
Total assets of Sk Biopharmaceuticals Co Ltd from 2016 to 2025. This chart illustrates how Sk Biopharmaceuticals Co Ltd's total assets have evolved over time, based on quarterly financial data. See Sk Biopharmaceuticals Co Ltd stock price for real-time trading data and today's change.
Sk Biopharmaceuticals Co Ltd - Asset Composition Analysis
Sk Biopharmaceuticals Co Ltd Total Assets Breakdown (December 2025)
Sk Biopharmaceuticals Co Ltd total assets breakdown as of December 2025. Sk Biopharmaceuticals Co Ltd's total assets of ₩1.32 Trillion consist of 57.0% current assets and 43.0% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 25.7% |
| Accounts Receivable | ₩228.83 Billion | 19.1% |
| Inventory | ₩100.24 Billion | 8.4% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩49.56 Billion | 4.1% |
| Goodwill | ₩1.65 Billion | 0.1% |
Asset Composition Trend (2016–2025)
This chart illustrates how Sk Biopharmaceuticals Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Sk Biopharmaceuticals Co Ltd (326030) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sk Biopharmaceuticals Co Ltd's current assets represent 57.0% of total assets in 2025, a decrease from 90.2% in 2016.
- Cash Position: Cash and equivalents constituted 25.7% of total assets in 2025, up from 19.9% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 19.1% of total assets.
Sk Biopharmaceuticals Co Ltd Competitors by Total Assets
Key competitors of Sk Biopharmaceuticals Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.88 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥725.73 Million |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥3.67 Billion |
Sk Biopharmaceuticals Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.49 | 1.84 | 5.66 |
| Quick Ratio | 2.19 | 1.49 | 5.17 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩464.73 Billion | ₩276.72 Billion | ₩415.97 Billion |
Sk Biopharmaceuticals Co Ltd - Advanced Valuation Insights
This section examines the relationship between Sk Biopharmaceuticals Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.60 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 15.6% |
| Total Assets | ₩1.20 Trillion |
| Market Capitalization | $4.12 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Sk Biopharmaceuticals Co Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Sk Biopharmaceuticals Co Ltd's assets grew by 15.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Sk Biopharmaceuticals Co Ltd (2016–2025)
The table below shows the annual total assets of Sk Biopharmaceuticals Co Ltd from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩1.20 Trillion ≈ $812.08 Million |
+15.58% |
| 2024-12-31 | ₩1.04 Trillion ≈ $702.63 Million |
+43.37% |
| 2023-12-31 | ₩723.17 Billion ≈ $490.08 Million |
+8.87% |
| 2022-12-31 | ₩664.24 Billion ≈ $450.15 Million |
+3.20% |
| 2021-12-31 | ₩643.65 Billion ≈ $436.19 Million |
+28.67% |
| 2020-12-31 | ₩500.24 Billion ≈ $339.01 Million |
+259.70% |
| 2019-12-31 | ₩139.07 Billion ≈ $94.25 Million |
+45.57% |
| 2018-12-31 | ₩95.54 Billion ≈ $64.74 Million |
-2.88% |
| 2017-12-31 | ₩98.37 Billion ≈ $66.66 Million |
-49.27% |
| 2016-12-31 | ₩193.89 Billion ≈ $131.40 Million |
-- |
About Sk Biopharmaceuticals Co Ltd
SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, development, and commercialization of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; Relenopride, wh… Read more